de Gonzalo-Calvo, David
Martinez-Camblor, Pablo
Belmonte, Thalia
Barbé, Ferran
Duarte, Kevin
Cowie, Martin R.
Angermann, Christiane E.
Korte, Andrea
Riedel, Isabelle
Labus, Josephine
Koenig, Wolfgang
Zannad, Faiez
Thum, Thomas
Bär, Christian
Funding for this research was provided by:
German Research Foundation (Project-ID 403584255-TRR 267)
Instituto de Salud Carlos III (Miguel Servet 2020: CP20/00041, PI20/00577, CIBERES CB07/06/2008)
Medizinische Hochschule Hannover (MHH)
Article History
Received: 11 April 2023
Accepted: 22 September 2023
First Online: 20 October 2023
Declarations
:
: TT is a founder and shareholder of Cardior Pharmaceuticals GmbH (outside the topic of this paper). CB and TT have filed patents on the use of circulating RNAs for diagnosis and prognosis of cardiovascular disease. WK reports advisory board fees from AstraZeneca, Novartis, Amgen, Pfizer, The Medicines Company, DalCor, Kowa, Corvidia, OMEICOS, Daiichi-Sankyo, Novo Nordisk, New Amsterdam Pharma, TenSixteen Bio, Esperion, Genentech; lecture fees from Bristol-Myers Squibb, Novartis, Amgen, Berlin-Chemie, Sanofi and AstraZeneca; grants and non-financial support from Abbott, Roche Diagnostics, Beckmann, and Singulex, all outside the submitted work. FZ reports personal fees from Applied Therapeutics, Bayer, Boehringer, BMS, CVRx, Cardior, Cereno pharmaceutical, Cellprothera, CEVA, Merck, Novartis, NovoNordisk, Owkin, Pfizer, Servier, having stock options at G3Pharmaceutical and equities at Cereno pharmaceutical, Cardiorenal, Eshmoun Clinical research and being the founder of Cardiovascular Clinical Trialists. CEA reports membership in the ServeHF Steering committee, and received consulting fees and honoraria from ResMed, in context with the current work. She further reports grant support, personal fees and/or non-financial support from Abbott, Astra-Zeneca, Boehringer Ingelheim & Eli Lilly Company, Biotronik, Novo Nordisk, Novartis, Thermo Fisher and Vifor, all outside of the submitted work. Members of the ServeHF Steering committee, received consulting fees and honoraria from ResMed, in context with current work